News
-
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union
Norgine receives EC authorization for XOLREMDI® for WHIM syndrome, the first treatment in the EU for this rare condition. Approval based on positive CHMP opinion and Phase 3 trial results